Lb Pharmaceuticals (LBRX) Net Income towards Common Stockholders (2024 - 2026)

Lb Pharmaceuticals' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$19.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 259.1% year-over-year to -$19.1 million; the TTM figure through Mar 2026 stood at -$14.2 million (changed N/A YoY), while the FY2025 annual figure was -$25205.0, up 60.06% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$19.1 million, down from $13.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $58.0 million in Q4 2024, with the low at -$19.1 million in Q1 2026.
• The 3-year median for Net Income towards Common Stockholders is -$4.4 million (2025), against an average of $4.9 million.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders soared 74.92% in 2025, then sank 259.1% in 2026.
• Lb Pharmaceuticals' Net Income towards Common Stockholders stood at $58.0 million in 2024, then slumped by 76.35% to $13.7 million in 2025, then plunged by 239.0% to -$19.1 million in 2026.
• Business Quant data shows LBRX's Net Income towards Common Stockholders at -$19.1 million in Q1 2026, $13.7 million in Q4 2025, and -$3.6 million in Q3 2025.